NCT00215462View on ClinicalTrials.gov

Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 30, 2000

Primary Completion Date

August 31, 2005

Study Completion Date

August 31, 2005

Conditions
Esophageal CancerGastric CancerStomach Cancer
Interventions
DRUG

Vinorelbine

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00215462 - Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma | Biotech Hunter | Biotech Hunter